US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cellcom Israel

3.77

0.0000

Volume:- -

Turnover:- -

Market Cap:613.66M

PE:-10.29

High:3.77

Open:3.77

Low:3.77

Close:3.77

52wk High:5.49

52wk Low:1.86

Shares:162.78M

Float Shares:84.30M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3664

EPS(LYR):-0.2617

ROE:-10.15%

ROA:-0.17%

PB:1.18

PE(LYR):-14.41

Loading ...

Overview Company News Filings

Press Release: CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Q4 EPS $(0.09) Beats $(0.11) Estimate

Press Release: CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Completes $5 Million 'Best Efforts' Stock Sale

MT Newswires Live

CEL-SCI Prices $5 Million Stock Offering

MT Newswires Live

Challenger Gold Announces Toll Processing Agreement & Strategic Placement Completion

BRIEF-US FDA And CEL-SCI Agree On Use Of PD-L1 Biomarker

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CEL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEL\",,,,,undefined,":{"symbol":"CEL","market":"US","secType":"STK","nameCN":"Cellcom Israel","latestPrice":3.77,"timestamp":1612818000000,"preClose":3.77,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":84298091,"shares":162775715,"eps":-0.366397,"marketStatus":"Delisted","change":0,"latestTime":"02-08 16:00:00 EST","open":3.77,"high":3.77,"low":3.77,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.366397,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1170738000000,"exchange":"NYSE","adjPreClose":3.77,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEL\",,,,,undefined,":{"symbol":"CEL","floatShares":84298091,"roa":"-0.17%","roe":"-10.15%","lyrEps":-0.261688,"shares":162775715,"dividePrice":0,"high":3.77,"amplitude":0,"preClose":3.77,"low":3.77,"week52Low":1.86,"pbRate":"1.18","week52High":5.49,"institutionHeld":0,"latestPrice":3.77,"eps":-0.366397,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.366397,"open":3.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-02-09","symbol":"CEL","reason":null,"defaultRemindTime":1612881000000,"announcedDate":"2021-02-04","type":"delisting","dateTimestamp":1612846800000},{"market":"US","date":"2020-11-23","symbol":"CEL","fiscalQuarterEnding":"2020/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1606107600000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2020-08-17","symbol":"CEL","fiscalQuarterEnding":"2020/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1597636800000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2020-05-21","symbol":"CEL","fiscalQuarterEnding":"2020/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1590033600000,"reportTimeType":"","actualEps":-0.08},{"market":"US","date":"2020-03-23","symbol":"CEL","fiscalQuarterEnding":"2019/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1584936000000,"reportTimeType":"","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CEL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CEL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512157767","title":"Press Release: CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2512157767","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512157767?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:30","pubTimestamp":1739885400,"startTime":"0","endTime":"0","summary":"CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks. CEL-SCI Corporation  today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments.\"CEL-SCI is very uniquely positioned at this moment as an immuno-oncology company with a vast amount of data from the largest Phase 3 head and neck cancer study ever performed, with statistically significant evidence that our drug can successfully fight cancer and extend lives in head and neck cancer,\" stated CEL-SCI CEO, Geert Kersten. \"We hope to deliver a new standard of care to patients while substantially transforming our company's valuation to reflect what we believe to be the intrinsic value of our cancer drug. The statistical analysis shows that our very soon to be initiated small confirmatory Registration Study has a very high chance of success and we will have indications of efficacy as early as 20","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4023","BK4528","BK4588","SAP","CVM","BK4139","CEL"],"gpt_icon":0},{"id":"2503576780","title":"CEL-SCI Q4 EPS $(0.09) Beats $(0.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2503576780","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503576780?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:20","pubTimestamp":1736864421,"startTime":"0","endTime":"0","summary":"CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.75 percent increase over losses of $(0.16) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/42974613/cel-sci-q4-eps-0-09-beats-0-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVM","CEL"],"gpt_icon":0},{"id":"2503575421","title":"Press Release: CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2503575421","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503575421?lang=en_us&edition=fundamental","pubTime":"2025-01-14 22:00","pubTimestamp":1736863200,"startTime":"0","endTime":"0","summary":"CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer. A 212-patient Confirmatory Registration Study for Multikine in PD-L1. low newly diagnosed head and neck cancer patients is currently in final. stage of start-up preparations - full enrollment expected by Q2 2026. Plans to seek early approval based on pre-surgical response rates. A positive study outcome will position Multikine as the first treatment. in over 50 years for newly diagnosed locally advanced head and neck. cancer patients -- a population with a severe unmet medical need. via biopsy). In this target population in the completed Phase 3 study,CEL-SCI selected Ergomed, a clinical research organization  with a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVM","BK4156","BK4139","BK4124","SMP","CEL"],"gpt_icon":0},{"id":"2500628350","title":"CEL-SCI Completes $5 Million 'Best Efforts' Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2500628350","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500628350?lang=en_us&edition=fundamental","pubTime":"2025-01-01 05:25","pubTimestamp":1735680300,"startTime":"0","endTime":"0","summary":"CEL-SCI  late Tuesday said it has closed on its best-efforts offering of more than 16.1 million common shares and prefunded warrants at $0.31 per share, generating $5 million in gross proceeds.The cancer immunotherapy company plans to use the net proceeds to continue development of its Multikine injections, as well as working capital and other general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CVM","CEL"],"gpt_icon":0},{"id":"2495459041","title":"CEL-SCI Prices $5 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2495459041","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495459041?lang=en_us&edition=fundamental","pubTime":"2024-12-30 16:41","pubTimestamp":1735548067,"startTime":"0","endTime":"0","summary":"CEL-SCI Corporation  said late Sunday it priced a best-efforts public offering of 16.1 million shares of common stock, or pre-funded warrants in lieu of common shares, at $0.31 per share for total expected gross proceeds of $5 million.Net proceeds will be used for product development, general corporate purposes, and working capital, the Vienna, Virginia company said.Closing of the offering is expected to occur on Dec. 31, subject to customary closing conditions.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CVM","BK4139","CEL"],"gpt_icon":0},{"id":"2495593881","title":"Challenger Gold Announces Toll Processing Agreement & Strategic Placement Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2495593881","media":"T-Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495593881?lang=en_us&edition=fundamental","pubTime":"2024-12-30 08:55","pubTimestamp":1735520146,"startTime":"0","endTime":"0","summary":"Challenger Gold Ltd :Toll Processing Agreement & Strategic Placement Completion.Final Binding Agreements For A$6.6M Strategic Placement Completed.Further Company Coverage: Cel.Ax. ((Reuters.Briefs@Thomsonreuters.Com;)).","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CEL"],"gpt_icon":0},{"id":"2481040719","title":"BRIEF-US FDA And CEL-SCI Agree On Use Of PD-L1 Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2481040719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481040719?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:18","pubTimestamp":1730985517,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - CEL-SCI Corp   :   * U.S. FDA AND CEL-SCI AGREE ON USE OF PD-L1 BIOMARKER TO SELECT HEAD AND NECK CANCER PATIENTS FOR MARKETING REGISTRATION STUDY TO COMMENCE Q1 2025Source text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4023","CEL","ADC","PD","LU1169590202.USD","BK4231","BK4080"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}